4dpharmaplc.com/en/newsroom...
About MRx0005 and MRx0029
MRx0005 and MRx0029 are oral single strain Live Biotherapeutic products in development for the treatment of neurodegenerative conditions such as Parkinson’s disease via the gut-brain axis. Discovered using 4D pharma’s MicroRx® platform, both have been shown pre-clinically to reduce neuroinflammation including inflammation induced by α-synuclein, and to protect neurons from oxidative stress-induced death. MRx0005 has been shown to upregulate expression of neuroactive molecules and their receptors in vivo, and protected against loss of dopamine metabolites in the brains of mice with induced parkinsonian syndrome. Impaired intestinal barrier function and intestinal permeability is a common symptom of Parkinson’s disease thought to potentially contribute to the onset or progression of the condition, and MRx0029 has been shown to improve intestinal epithelial integrity. MRx0029 has also been shown to induce the differentiation of dopaminergic neuronal phenotype in vitro, and in an animal model of Parkinson’s disease protected against the loss of dopaminergic neurons. In 2022, 4D pharma plans to commence a Phase I clinical trial of both MRx0005 and MRx0029, separately, in people with Parkinson’s disease.
---------------------------------------------
STAY STRONG EVERYONE!
A MIRACLE IS AROUND THE NEXT CORNER!
The Endotoxin Hypothesis of Parkinson's Disease
Method generates dopaminergic neurons lost in Parkinson’s disease
Colostrum: the most important nutrient for the prevention of chronic conditions
Methylphenidate for \"Parkinson's\"
